Longevity Capital Meets Longevity Demand

Fresh venture capital is flowing into cellular-diagnostic and regenerative skincare — a $100M+ fund from Beiersdorf and a $20M raise for Rapalogix, whose work targets the TORC1 cellular pathway. This is capital chasing the same longevity science that underpins programs at Clinique La Prairie, SHA Wellness, and Lanserhof, and it typically arrives at those properties first as new diagnostic add-ons and premium-priced treatment tiers before reaching mainstream spas.

For advisors, the practical takeaway is timing and diligence: expect updated menus and pricing at longevity-focused properties within the next booking cycle, but vet the clinical claims carefully. The category is already drawing 'longevity-washing' scrutiny — cellular-diagnostic marketing that outpaces the evidence — so treat new treatment names as a prompt to ask properties directly what's actually been validated before positioning them to clients.

Tom Brady is backing eMed's push to make GLP-1 access an employer-paid benefit, part of a company now valued near $2 billion. GLP-1 coverage has become one of the most-requested workplace health benefits, and that demand doesn't stop at the prescription — it's already reshaping what medical-wellness operators build around it.

Expect SHA Wellness, Lanserhof, Mayrlife, and similar programs to keep expanding GLP-1-adjacent offerings: muscle-preservation protocols, metabolic-reset weeks, and post-medication recalibration stays. For advisors, this is a corporate and executive wellness opening — employers footing the GLP-1 bill are a natural audience for pairing that benefit with a structured retreat, and properties with dedicated GLP-1-support programming now have a concrete selling point over generic spa stays.